Carbidopa and L-Dopa Prodrugs and Methods of Use

A pharmaceutical combination comprising a first compound corresponding in structure to Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, —P(O)(OH)2, and —R5—O—P(O)(OH)2;
• R5 is a C1-C4-alkyl;
• R6 is hydrogen or a C1-C4-alkyl;
• and provided that at least one of R1 and R2 is —P(O)(OH)2 or —R5—O—P(O)(OH)2;
• and
• a second compound corresponding in structure Formula (II):
• or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are each independently selected from the group consisting of hydrogen, —P(O)(OH)2, and —R5—O—P(O)(OH)2;
• R5 is a C1-C4-alkyl;
• R6 is hydrogen or a C1-C4-alkyl;
• and provided that at least one of R3 and R4 is —P(O)(OH)2 or —R5—O—P(O)(OH)2.